Filing Flows

Filing Flows › Companies › Ovid Therapeutics › Cash flow

Ovid Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$17.6M in Q2 2026 · −$54.8M over twelve months

Operating cash flow−$17.6M
Free cash flow−$17.6M

Analysis

In Q2 2026, Ovid Therapeutics generated −$17.6M of operating cash flow. That is $12.8M less than in Q2 2025 (−$4.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$54.8M; the largest uses were other investing ($148M), operating cash flow ($54.8M); besides operations, cash came from other financing ($185M), shares issued ($305K); the cash balance fell by $17.1M.

Operating cash flow was −$17.6M against net income of −$15.0M. The largest differences: prepaid and other assets −$1.8M, payables −$1.5M, stock-based pay +$1.4M.

Free cash flow

Ovid Therapeutics: free cash flow by quarterOvid Therapeutics: free cash flow by quarter−$15.0MQ3 2024−$10.0MQ4 2024−$10.3MQ1 2025−$4.8MQ2 2025−$12.9MQ3 2025−$10.4MQ4 2025−$13.9MQ1 2026−$17.6MQ2 2026
Operating cash flow less capital spending.
Ovid Therapeutics: operating cash flow against capital spendingOvid Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$15.0M−$4KQ3 2024−$10.0M$22KQ4 2024−$10.3M$0Q1 2025−$4.8M$0Q2 2025−$12.9M$0Q3 2025−$10.4M$0Q4 2025−$13.9M$0Q1 2026−$17.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$17.6M, Capital spending $0.

Capital allocation, year by year

Ovid Therapeutics: where the cash came from (up) and went (down), by fiscal yearOvid Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow $119MFY2021: Shares issued $925KFY2021: Capital spending −$184K$120MFY2021FY2022: Operating cash flow −$55.2MFY2022: Shares issued $181KFY2022: Capital spending −$1.2M$181KFY2022FY2023: Operating cash flow −$45.8MFY2023: Shares issued $535KFY2023: Capital spending −$40K$535KFY2023FY2024: Operating cash flow −$56.0MFY2024: Shares issued $622KFY2024: Capital spending −$71K$622KFY2024FY2025: Operating cash flow −$38.3MFY2025: Shares issued $91K$91KFY2025
Over these 5 years operating cash flow totalled −$76.7M; the largest uses were operating cash flow ($195M) and capital spending ($1.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$117M
Debtnone
Net cash$117M
Cash runway2.1 years

Ovid Therapeutics is burning cash: its operations consume cash, a free cash flow of −$54.8M a year at the current rate against $117M of cash and investments: a runway of about 2.1 years before any new financing.

Where the cash came from and went

Ovid Therapeutics: sources (+) and uses (−) of cash, Q2 2026Ovid Therapeutics: sources (+) and uses (−) of cash, Q2 2026Other investing−$86.7MCash drawn (+) / kept (−)$82.7MOther financing$21.6MOperating cash flow−$17.6MShares issued$8KExchange rates−$4K
Ovid Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Ovid Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$185MOther investing−$148MOperating cash flow−$54.8MCash drawn (+) / kept (−)$17.1MShares issued$305KExchange rates−$293K

From profit to cash

Ovid Therapeutics: net income to operating cash flow, Q2 2026Ovid Therapeutics: net income to operating cash flow, Q2 2026Net income−$15.0MDepreciation & amortization$16KStock-based pay$1.4MPayables−$1.5MAccrued liabilities−$352KPrepaid and other assets−$1.8MOperating cash flow−$17.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$17.6M—$8K$82.7M−$17.6M
Q1 2026−$13.9M—$2.6M−$80.9M−$13.9M
Q4 2025−$10.4M—$63K$7.3M−$10.4M
Q3 2025−$12.9M—$15K$7.8M−$12.9M
Q2 2025−$4.8M——−$7.3M−$4.8M
Q1 2025−$10.3M—$13K$5.2M−$10.3M
Q4 2024−$10.0M−$22K—−$11.3M−$10.0M
Q3 2024−$15.0M$4K$38K$14.7M−$15.0M

Ovid Therapeutics: income statement and cash flow

Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year). The chart follows the revenue to costs, profit and cash.

Ovid Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.